Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2002

View Archived Issues

Landmark LIPS trial demonstrates significant reduction in risk of cardiac events on fluvastatin

Rationally designed anticancer drugs targeting key enzymes as a new approach to breast cancer

OCTAVE and OVERTURE results for Vanlev disclosed by BMS

HSV-1 glycoprotein D vaccine affords high and sustained protective immunity in animal models

Pharmacokinetics, oral bioavailability of potential new agent for HCMV

Xoma summarizes highlights of 2001

Anti-TNF antibodies prepared by scientists at Centocor

Vaccine for West Nile virus highly effective in mice, slated for clinical trials this year

Centocor patents series of anti-IL-12 antibodies

Compounds for cancer gene therapy reported by Fujisawa

Investigators at Shiseido identify new MMP inhibitors

Inhibitors of IL-1beta production synthesized at Kowa

Research at Ono leads to the design of new PDE4 inhibitors

Aventis discloses compounds active against telomerase

NeoTherapeutics presents summary of 2001 results

American College of Cardiology meeting highlights available to Daily Essentials readers

FDA advisory committee votes against recommending approval of Picovir

Canadian IND approval for buccal morphine in the treatment of pain

Phase III open-label study of Alprox-TD begins in male erectile dysfunction

Multiple phase III trials initiated for NBI-34060 in insomnia

Irofulven tested in cancer patients in combination with cisplatin

Antares Pharma and MacroMed team up to develop depot delivery systems

Alliance and Inhale expand PulmoSpheres agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...